Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.
A unit of Johnson & Johnson will pay $360 million to resolve an investigation into the company’s financial support of a charity that helped Medicare patients cover out-of-pocket drug costs.
U.S. biotechnology company Clovis Oncology Inc., Chief Executive Patrick Mahaffy, and former CFO Erle Mast will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said.
Osiris Therapeutics settled a case of accounting fraud with the U.S. SEC, but four former company executives will face charges for the alleged financial misreporting.
The U.S. Justice Department joined a whistleblower lawsuit against UnitedHealth Group Inc. that claims the country’s largest health insurer and its units and affiliates overcharged Medicare hundreds of millions of dollars, a law firm representing the whistleblower said.
Turkey’s investigation into Novartis for bribery allegations is “ongoing,” a Turkish health ministry official told Reuters, after the drugmaker said it was not under investigation.
Attorney General Loretta E. Lynch stands during the announcement of law enforcement action against the state of North Carolina in Washington, U.S., May 9, 2016. Reuters/Joshua Roberts/File Photo The U.S. Justice Department said Wednesday that federal law enforcement officials have hit a milestone in 2016 by completing the “largest takedown ever” against defendants allegedly trying […]
The Ankara Chief Prosecutor has launched an investigation into the Turkish unit of Swiss drugmaker Novartis after allegations the company benefited from bribery.
February 18, 2016 By Alex Keown, BioSpace.com Breaking News Staff NEW ORLEANS — The once promising Renaissance RX, a personalized medicine firm specializing in genetic testing, is facing allegations of fraud in an employee lawsuit, the Advocate of Louisiana reported Wednesday. Alison Diboll, who relocated to New Orleans from California to take a marketing […]
PHOENIX – After its stock dropped nearly 20 percent, Insys Therapeutics defended its practices from allegations it falsified data in order to sell more of its painkiller, the fentanyl-based Subsys. The Arizona-based company said it is committed to patient safety and has complied with all law, including those related to adverse event reporting. In […]